1887

Abstract

Guinea pigs were administered antiserum 24 h (As+24) or 72 h (As+72) after intravaginal herpes simplex virus type 2 (HSV-2) challenge. Treatment at either time reduced acute virus replication in the dorsal root ganglia and the overall magnitude of replication in the genital tract. In two studies, As+24 treatment significantly reduced the severity of primary genital skin disease and the frequency of subsequent spontaneous recurrent disease. In contrast, As+72 treatment produced a modest reduction in primary disease severity but did not impact on recurrent disease. Quantitative PCR analysis of dorsal root ganglia DNA from latently infected animals showed that As+24 treatment produced a significantly reduced viral DNA burden, which appeared to correlate with the reduction in recurrent disease. The amount of DNA in the ganglia of As+72-treated animals was not significantly lower than that of controls. These observations have implications for both the dynamics of latency establishment and desirable vaccine characteristics.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-11-2797
2002-11-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/11/0832797a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-11-2797&mimeType=html&fmt=ahah

References

  1. Bernstein, D. I. & Harrison, C. J. ( 1989; ). Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections. Antimicrobial Agents and Chemotherapy 33, 1511-1515.[CrossRef]
    [Google Scholar]
  2. Bernstein, D. I., Stanberry, L. R., Harrison, C. J., Kappes, J. & Myers, M. G. ( 1986; ). Antibody response, recurrence pattern and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea pigs: effects of acyclovir. Journal of General Virology 67, 1601-1612.[CrossRef]
    [Google Scholar]
  3. Bourne, N., Stanberry, L. R., Bernstein, D. I. & Lew, D. ( 1996; ). DNA immunization against experimental genital herpes simplex virus infection. Journal of Infectious Diseases 173, 800-807.[CrossRef]
    [Google Scholar]
  4. Kavaliotis, J., Loukou, I., Trachana, M., Gombakis, N., Tsargaropoulou-Stigga, H. & Koliouskas, D. ( 1998; ). Outbreak of varicella in a pediatric oncology unit. Medical and Pediatric Oncology 31, 166-169.[CrossRef]
    [Google Scholar]
  5. Klein, R. J. ( 1980; ). Effect of immune serum on the establishment of herpes simplex virus infection in trigeminal ganglia of hairless mice. Journal of General Virology 49, 401-405.[CrossRef]
    [Google Scholar]
  6. McKendall, R. R., Klassen, T. & Baringer, J. R. ( 1979; ). Host defenses in herpes simplex infections of the nervous system: effect of antibody on disease and viral spread. Infection and Immunity 23, 305-311.
    [Google Scholar]
  7. Morrison, L. A., Zhu, L. & Thebeau, L. G. ( 2001; ). Vaccine-induced serum immunoglobulin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. Journal of Virology 75, 1195-1204.[CrossRef]
    [Google Scholar]
  8. Oakes, J. E. & Rosemund-Hornbeak, H. ( 1978; ). Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection. Infection and Immunity 21, 489-495.
    [Google Scholar]
  9. Sawyer, L. A. ( 2000; ). Antibodies for the prevention and treatment of viral diseases. Antiviral Research 47, 57-77.[CrossRef]
    [Google Scholar]
  10. Shimeld, C. T., Hill, J., Blyth, W. A. & Easty, D. L. ( 1990; ). Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system. Journal of General Virology 71, 681-687.[CrossRef]
    [Google Scholar]
  11. Snydman, D. R. ( 1990; ). Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease. Reviews of Infectious Diseases 12 (Suppl. 7), 839–847.
    [Google Scholar]
  12. Stanberry, L. R., Kern, E. R., Richards, J. T., Abbott, T. M. & Overall, J. C.Jr ( 1982; ). Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. Journal of Infectious Diseases 146, 397-401.[CrossRef]
    [Google Scholar]
  13. Stanberry, L. R., Kern, E. R., Richards, J. T. & Overall, J. C.Jr ( 1985; ). Recurrent genital herpes simplex virus infection in guinea pigs. Intervirology 24, 226-231.[CrossRef]
    [Google Scholar]
  14. Stanberry, L. R., Bernstein, D. I., Burke, R. L., Pachl, C. & Myers, M. G. ( 1987; ). Recombinant herpes simplex virus glycoprotein vaccine protects against initial and recurrent genital herpes. Journal of Infectious Diseases 155, 397-404.
    [Google Scholar]
  15. Wachsman, M., Kulka, M., Smith, C. C. & Aurelian, L. ( 2001; ). A growth and latency compromised herpes simplex virus type 2 mutant (ICP10ΔPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 19, 1879-1890.[CrossRef]
    [Google Scholar]
  16. Walz, M. A., Yamamoto, H. & Notkins, A. L. ( 1976; ). Immunologic response restricts number of cells in sensory ganglia infected with herpes simplex virus. Nature 264, 554-556.[CrossRef]
    [Google Scholar]
  17. Zaia, J. A., Levin, M. J., Preblud, S. R., Leszczynski, J., Wright, G. G., Ellis, R. J., Curtis, A. C., Valerio, M. A. & LeGore, J. ( 1983; ). Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. Journal of Infectious Diseases 147, 737-743.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-11-2797
Loading
/content/journal/jgv/10.1099/0022-1317-83-11-2797
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error